Physician
Thakkar, Ruchir
Thakkar, Ruchir was paid $8.22M by Medicaid between Mar 2018 and Sep 2024, across 113 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 16% of everything it billed.
33Billing provider infoTHAKKAR, RUCHIR
CICERO, IL 60804
CICERO, IL 60804
33aNPI1174812853assigned 04/01/2011
33bProvider typeFamily Medicine Physician
28Total paid$8.22M
24GClaims222,782
24DCodes billed113
24AFirst – last monthMar 2018 – Sep 2024
Compared with peers
Next to other Family Medicine Physician providers in Illinois
Rank by total paid#10 of 2,947
Median peer was paid$43K
This provider vs. median193×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,849 | $96K | |
| 2019 | 20,434 | $670K | |
| 2020 | 37,067 | $1.42M | |
| 2021 | 61,030 | $2.48M | |
| 2022 | 62,510 | $2.13M | |
| 2023 | 21,035 | $680K | |
| 2024incomplete | 17,857 | $739K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 27,479 | 19,709 | $1.33M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.2% | 19,373 | 12,667 | $676K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.2% | 8,837 | 6,130 | $673K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 7.6% | 13,412 | 10,478 | $624K |
| 99243 | 6.0% | 4,989 | 4,120 | $495K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.7% | 9,224 | 7,177 | $470K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.5% | 4,751 | 3,420 | $372K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.1% | 4,748 | 4,002 | $337K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.4% | 3,691 | 2,709 | $282K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.0% | 10,665 | 6,675 | $246K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.8% | 4,714 | 3,539 | $228K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.7% | 4,674 | 3,515 | $225K |
101 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.7% | 5,011 | $218K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.6% | 885 | $129K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.6% | 1,641 | $128K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 4,160 | $121K |
| 87634 | 1.2% | 1,898 | $98K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.1% | 3,102 | $89K |
| 87481 | 1.1% | 1,651 | $89K | |
| 86696 | <1% | 2,543 | $70K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 825 | $65K |
| 99401 | <1% | 2,196 | $64K | |
| 87503 | <1% | 3,543 | $62K | |
| 96160 | <1% | 4,012 | $58K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 769 | $58K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,195 | $55K |
| 86695 | <1% | 2,602 | $55K | |
| 99385 | <1% | 482 | $46K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 274 | $39K |
| 86803 | <1% | 2,301 | $39K | |
| 94760 | <1% | 9,956 | $38K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,400 | $37K |
| 87186 | <1% | 1,713 | $36K | |
| 80053 | Comprehensive metabolic panel | <1% | 3,160 | $32K |
| 99384 | <1% | 305 | $31K | |
| 87510 | <1% | 1,187 | $31K | |
| 86704 | <1% | 1,763 | $28K | |
| 80074 | <1% | 705 | $27K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 193 | $27K |
| 86706 | <1% | 1,801 | $25K | |
| 99383 | <1% | 266 | $25K | |
| 96127 | <1% | 1,675 | $24K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 226 | $22K |
| 87088 | <1% | 1,989 | $22K | |
| 87563 | <1% | 535 | $22K | |
| 87340 | <1% | 1,580 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,004 | $21K |
| 81025 | <1% | 3,816 | $19K | |
| 81001 | <1% | 6,239 | $18K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,070 | $17K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 203 | $17K |
| 87070 | <1% | 2,676 | $16K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 519 | $15K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 604 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,596 | $15K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 168 | $13K |
| 87511 | <1% | 334 | $13K | |
| 86592 | <1% | 2,871 | $11K | |
| 92551 | <1% | 746 | $11K | |
| 86705 | <1% | 599 | $9K | |
| 94010 | <1% | 240 | $9K | |
| 99173 | <1% | 1,039 | $8K | |
| 86780 | <1% | 406 | $7K | |
| 94060 | <1% | 127 | $6K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 187 | $6K |
| 81002 | <1% | 2,236 | $6K | |
| 87428 | <1% | 85 | $5K | |
| 86146 | <1% | 99 | $5K | |
| 99070 | <1% | 572 | $4K | |
| 87500 | <1% | 146 | $4K | |
| 87641 | <1% | 114 | $4K | |
| 99382 | <1% | 43 | $4K | |
| 87640 | <1% | 105 | $4K | |
| 86709 | <1% | 603 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 226 | $4K |
| 87581 | <1% | 89 | $3K | |
| 81003 | <1% | 1,165 | $3K | |
| 86694 | <1% | 172 | $2K | |
| 86580 | <1% | 414 | $2K | |
| 86769 | <1% | 27 | $2K | |
| 87529 | <1% | 28 | $2K | |
| 86707 | <1% | 204 | $2K | |
| 90715 | <1% | 85 | $2K | |
| 87561 | <1% | 38 | $2K | |
| 87400 | <1% | 96 | $2K | |
| 87807 | <1% | 159 | $2K | |
| 84481 | <1% | 156 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 246 | $2K |
| 84439 | <1% | 151 | $1K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14 | $1K |
| 80061 | Lipid panel | <1% | 170 | $970.09 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 66 | $848.92 |
| 87480 | <1% | 34 | $681.70 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 102 | $675.66 |
| 83721 | <1% | 82 | $653.80 | |
| 83026 | <1% | 237 | $543.84 | |
| 0011A | <1% | 13 | $520.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 391 | $502.31 |
| 82728 | <1% | 52 | $372.32 | |
| 69210 | <1% | 17 | $363.80 | |
| 82962 | <1% | 182 | $329.67 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 36 | $328.98 |
| 87081 | <1% | 55 | $319.00 | |
| 82947 | <1% | 85 | $305.60 | |
| 90658 | <1% | 29 | $303.22 | |
| 93000 | <1% | 13 | $287.95 | |
| 85018 | <1% | 116 | $269.12 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 17 | $150.62 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 73 | $99.84 |
| 83690 | <1% | 13 | $87.36 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 132 | $19.58 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 22 | $0.00 |
| 91301 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.